We searched for full-text English language articles in the PubMed database with the search terms “systemic lupus”, “lupus nephritis”, “DMARDs”, “biologics”, “remission”, “treat to target”, “antimalarials”, “calcineurin inhibitors”, “MMF/mycophenolate”, “rituximab”, “Jak inhibition”, “atacicept”, “belimumab”, “ustekinumab”, and “new therapies”, alone and in specific combinations. The date of our last search was Jan 31, 2019. We evaluated the retrieved papers and selected the most appropriate
ReviewNovel paradigms in systemic lupus erythematosus
Introduction
Systemic lupus erythematosus (SLE) is not only the prototypic systemic autoimmune disease, but also one of the most heterogeneous illnesses treated by physicians (panel 1). This heterogeneity presents immense challenges to diagnosis, treatment, and therapeutic advances. Despite these hurdles, SLE mortality has declined from 50% in the pre-corticosteroid era (circa 1948) to a 15-year survival of 85–95% in the modern era.1, 2 Although new therapies are largely responsible for improved outcomes, earlier diagnosis and better management of specific organ manifestations and complications, particularly those related to lupus nephritis, have also benefited patients. However, excessive damage accrual, morbidity, and mortality remain,3 indicating that a substantial medical need in SLE still exists. This Review highlights recent advances in the field and presents current treatment algorithms, the new European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR) classification of SLE, new outcome measures, a proposal to modify the histological classification of lupus nephritis, and novel drug development strategies.
Section snippets
Epidemiology
The prevalence of SLE has been estimated to be 30–50 per 100 000, which equates to approximately 500 000 patients in Europe and 250 000 in the USA.4, 5 An analysis published in 2017 provided evidence that ancestry, race, and ethnicity have major impacts on SLE manifestations and severity.6 The incidence and prevalence of SLE are higher in black, Asian, and Hispanic patients, who tend to develop lupus earlier and have more severe and more active disease, with long-term disease damage and
Treatment goals
SLE treatment goals must be balanced by taking multiple disease-specific and patient-specific aspects into consideration, especially the individual profile of involved organ manifestations. Although the disease itself can cause severe and irreversible damage, therapeutics such as glucocorticoids or cyclophosphamide can contribute to damage or have substantial toxic effects.3 Thus, the development of an individual treatment strategy is rather complex with the ultimate challenge to reduce disease
Treatment goals
The preservation of quality of life through the achievement of clinical improvement during a 6–12 month induction phase followed by a maintenance phase that prevents further organ damage is the goal of lupus nephritis treatment. Joint recommendations for lupus nephritis treatment have been published by EULAR and the European Renal Association–European Dialysis and Transplant Association31 and the ACR32 (figure 3).
A return to pre-nephritic flare creatinine clearance is the goal. However, given
Treat to target, lupus low disease activity, and remission in SLE
Successful treat-to-target strategies have improved outcomes for patients with diabetes, hypertension, or rheumatoid arthritis. Adapting a similar approach, initiatives in SLE have defined treatment goals, which range from an operational definition of LLDAS22 (panel 2) to remission definitions (panel 3).23, 94 They serve multiple purposes, chief of which is the association with diminished damage accrual and mortality.
LLDAS in SLE22, 95 has been associated with reduced damage accrual. The
Conclusions
The future for patients with SLE is bright. The disease is being attacked from all sides to gain better insights so that remission is a possibility for more patients, and morbidity and mortality are greatly reduced. These goals will be achieved through the broad efforts of basic, translational, and clinical scientists, clinicians, patients and their families, allied professionals, and everyone engaged in the lupus community.
Search strategy and selection criteria
References (111)
- et al.
Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study
J Autoimmun
(2018) - et al.
Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision)
Ophthalmology
(2016) - et al.
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Lancet
(2011) - et al.
Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Kidney Int
(2019) - et al.
Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices
Kidney Int
(2018) - et al.
Induction and maintenance immunosuppression treatment of proliferative lupus nephritis: a network meta-analysis of randomized trials
Am J Kidney Dis
(2017) Calcineurin inhibitors in systemic lupus erythematosus
Best Pract Res Clin Rheumatol
(2017)- et al.
Tacrolimus use in lupus nephritis: a systematic review and meta-analysis
Autoimmun Rev
(2016) - et al.
Systematic review, and meta-analysis of steroid-sparing effect, of biologic agents in randomized, placebo-controlled phase 3 trials for systemic lupus erythematosus
Semin Arthritis Rheum
(2018) - et al.
A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis
Kidney Int
(2019)
Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016
Ann Rheum Dis
46-year trends in systemic lupus erythematosus mortality in the United States, 1968 to 2013: a nationwide population-based study
Ann Intern Med
The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults
Rheumatology (Oxford)
EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics
Ann Rheum Dis
Population-based lupus registries: advancing our epidemiologic understanding
Arthritis Rheum
The effect of ethnicity and genetic ancestry on the epidemiology, clinical features and outcome of systemic lupus erythematosus
Rheumatology (Oxford)
First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR)
Ann Rheum Dis
Performance of antinuclear antibodies for classifying systemic lupus erythematosus: a systematic literature review and meta-regression of diagnostic data
Arthritis Care Res (Hoboken)
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus
Arthritis Rheum
Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus
Arthritis Rheum
Antinuclear antibody-negative systemic lupus erythematosus in an international inception cohort
Arthritis Care Res (Hoboken)
Multicenter Delphi exercise to identify important key items for classifying systemic lupus erythematosus
Arthritis Care Res (Hoboken)
Early symptoms of systemic lupus erythematosus (SLE) recalled by 339 SLE patients
Lupus
International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies
Ann Rheum Dis
ANA screening: an old test with new recommendations
Ann Rheum Dis
Assay variation in the detection of antinuclear antibodies in the sera of patients with established SLE
Ann Rheum Dis
Prevalence of anti-DFS70 antibodies in patients with and without systemic autoimmune rheumatic diseases
Clin Exp Rheumatol
Cell-bound complement activation products in SLE
Lupus Sci Med
The SLE-key test serological signature: new insights into the course of lupus
Rheumatology (Oxford)
Are interferon-related biomarkers advantageous for monitoring disease activity in systemic lupus erythematosus? A longitudinal benchmark study
Rheumatology (Oxford)
Definition and initial validation of a lupus low disease activity state (LLDAS)
Ann Rheum Dis
A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)
Ann Rheum Dis
The assessment of disability: from first to future principles
Br J Rheumatol
Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care
Lupus
Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis
Ann Rheum Dis
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Ann Rheum Dis
Antiphospholipid syndrome: state of the art on clinical practice guidelines
RMD Open
New therapeutic strategies in systemic lupus erythematosus management
Nat Rev Rheumatol
Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
Ann Rheum Dis
American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis
Arthritis Care Res (Hoboken)
EULAR recommendations for neuropsychiatric systemic lupus erythematosus vs usual care: results from two European centres
Rheumatology (Oxford)
An evidence-based approach to pre-pregnancy counselling for patients with systemic lupus erythematosus
Rheumatology (Oxford)
Treatment algorithms in systemic lupus erythematosus
Arthritis Care Res (Hoboken)
Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L)
Ann Rheum Dis
Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect
Lupus
Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients
Curr Rheumatol Rep
Longterm hydroxychloroquine therapy and low-dose aspirin may have an additive effectiveness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus
J Rheumatol
The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus
J Rheumatol
Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual
Arthritis Rheum
Cited by (349)
Autoimmune and auto-inflammatory adverse events after COVID-19 vaccination in the United States
2024, Clinical ImmunologyEngineered stem cells by emerging biomedical stratagems
2024, Science BulletinMicroplastics exposure induced and exacerbated the development of systemic lupus erythematosus in mice
2024, Science of the Total EnvironmentTreatment of systemic lupus erythematosus: New therapeutic options
2023, Revista Clinica EspanolaMicroglia orchestrate synaptic and neuronal stripping: Implication in neuropsychiatric lupus
2024, Journal of Cellular and Molecular Medicine